Service d’oncologie médicale, Groupe hospitalier Pitié-Salpêtrière, Paris, France, Département de médecine, institut Gustave-Roussy, Villejuif, France, Service d’oncohématologie, hôpital l’Archet, Nice, France
Protein kinase C (PKC) are cytoplasmic serine–threonine kinases, analysis of their involvement in oncogenesis is complex. Deregulated expressions of certain PKC can be observed in various tumors, but there is great variability in the roles of these enzymes according isoform or cell type (pro- or anti-proliferative action). Although understanding of the role of PKC in tumor development is still incomplete, different agents are currently evaluated. This review discusses the available data, with special emphasis on clinical outcomes.